Lista de obras - Ezia Bello - Dominio Público Uruguay

A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma.

artículo científico publicado en 2014

A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.

artículo científico publicado en 2017

A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells

scientific article published on 22 August 2019

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2017

Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo

artículo científico publicado en 2012

Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring

artículo científico publicado en 2006

Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials

article

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

artículo científico publicado en 2009

Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas

artículo científico publicado en 2019

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

artículo científico publicado en 2013

Detection of tissue-specific effects by methotrexate on differentiating mouse embryonic stem cells

artículo científico publicado en 2004

E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models

artículo científico publicado en 2011

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin

artículo científico publicado en 2019

Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.

artículo científico publicado en 2015

HPLC-MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E-3810 in tumor tissues from xenograft mice and human biopsies.

artículo científico publicado en 2014

HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model

artículo científico publicado en 2015

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.

artículo científico publicado en 2016

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models

artículo científico publicado en 2017

Mode of action of trabectedin in myxoid liposarcomas.

artículo científico publicado en 2013

Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

artículo científico publicado en 2010

PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers

artículo científico publicado en 2015

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

artículo científico publicado en 2017

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts

artículo científico publicado en 2016

Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin

artículo científico publicado en 2018

Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients

artículo científico publicado en 2018

The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats

artículo científico publicado en 2009

The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts

artículo científico publicado en 2012

Lista de obras de Ezia Bello

A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma.

A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.

A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo

Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring

Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

Detection of tissue-specific effects by methotrexate on differentiating mouse embryonic stem cells

E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin

Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.

HPLC-MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E-3810 in tumor tissues from xenograft mice and human biopsies.

HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models

Mode of action of trabectedin in myxoid liposarcomas.

Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts

Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin

Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients

The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats

The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts